A Phase 3 interventional study of Asciminib and Bosutinib in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 88 sites in 25 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 5th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 3, and was the 2nd registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Thomas Ernst, Prof. Dr. med. · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Spain
Ages 18+
Novartis Pharmaceuticals · Sites in France
Ages 18–99
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 5 · Phase 4 2
First in 2014; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 233 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 100 across the 21 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 15th largest by enrollment of the 63 interventional ones that give a count, is the only one that started in 2017, is one of 19 in phase 3, and was the 60th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
2 of the studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03906292University of JenaFrontline Asciminib Combination in Chronic Phase CML | 2027-03 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The purpose of this pivotal study was to compare the efficacy of asciminib (ABL001) with that of bosutinib in the treatment of participants with chronic myeloid leukemia - chronic phase (CML-CP) having previously been treated with a minimum of two prior ATP-binding site tyrosine kinase inhibitors (TKIs).
Participants with a diagnosis of CML-CP who had received prior treatment with 2 or more ATP binding site TKIs and were treatment failure (as per guidelines adapted from the 2013 ELN recommendations) or intolerant to the most recent TKI.
Participants were randomized in a 2:1 ratio to asciminib 40 mg BID or bosutinib 500 mg QD. Randomization was stratified by major cytogenetic response (MCyR) at screening.
Participants with documented treatment failure (as per the 2013 ELN recommendations) while on bosutinib treatment were offered the option to switch to asciminib treatment within 96 weeks after the last patient was randomized to the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female patients with a diagnosis of CML-CP ≥ 18 years of age
Patients must meet all of the following laboratory values at the screening visit:
BCR-ABL1 ratio > 0.1% IS according to central laboratory at the screening examination for patients intolerant to the most recent TKI therapy
Prior treatment with a minimum of 2 prior ATP-binding site TKIs (i.e. imatinib, nilotinib, dasatinib, radotinib or ponatinib)
Failure (adapted from the 2013 ELN Guidelines Bacarrani 2013) or intolerance to the most recent TKI therapy at the time of screening
Exclusion Criteria:
Known presence of the T315I or V299L mutation at any time prior to study entry Known second chronic phase of CML after previous progression to AP/BC Previous treatment with a hematopoietic stem-cell transplantation Patient planning to undergo hematopoietic stem cell transplantation
Cardiac or cardiac repolarization abnormality, including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were randomized to asciminib 40mg BID
Drug: Asciminib
Patients were randomized to bosutinib 500mg QD
Drug: Bosutinib
Major Molecular Response (MMR) Rate at 24 Weeks
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
Time frame: 24 weeks
Major Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint)
MMR at 96 weeks was defined as the percentage of participants with MMR at 96 weeks. MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
Time frame: 96 Weeks
Complete Cytogenetic Response (CCyR) Rate at Scheduled Time Points
Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.
Time frame: at 24, 48, 72, 96, 120 and 144 weeks
Complete Cytogenetic Response Rate by Scheduled Time Points
Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.
Time frame: by 24, 48, 72, 96, 120 and 144 weeks
Major Molecular Response (MMR) Rate at All Scheduled Data Collection Time Points Except Weeks 24 & 96
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
Time frame: at Weeks 36, 48, 60, 72, 84, 108, 120, 132, 144 & 156
Major Molecular Response (MMR) Rate by All Scheduled Data Collection Time Points
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR. Overall time point has the count indicating participants achieving MMR at any time during the study.
Time frame: by Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 & 156, Overall
Time to Major Molecular Response (MMR)
Time to MMR was defined as the time from the date of randomization to the date of the first documented MMR.
Time frame: 216 Weeks
Duration of Major Molecular Response (MMR)
Duration of MMR was defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to Accelerated phase (AP) or Blast crisis (BC), or Chronic myeloid leukemia (CML)-related death.
Time frame: 216 Weeks
Time to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR
Time to CCyR was defined as the time from the date of randomization to the date of the first documented CCyR.
Time frame: 216 Weeks
Duration of Complete Cytogenetic Response (CCyR)
Duration of CCyR was defined as the time between date of first documented CCyR and the earliest date of loss of CCyR, progression to AP/BC, or CML-related death for participants in the Cytogenetic Responder Set. The time was censored at the last cytogenetic assessment date on treatment for participants for whom none of the events was reported or last PCR evaluation on treatment indicating MMR.
Time frame: 144 weeks
Time to Treatment Failure (TTF)
TTF was defined as the time from date of randomization to an event of treatment failure. Treatment failure was defined as meeting a lack of efficacy criterion or discontinuing treatment due to any reason.
Time frame: From the first dose of treatment up to 5 years, through treatment completion, an average of 2.3 years, approximately
Progression Free Survival Per Percentage Event-free Kaplan-Meier Estimates
Progression-free survival was defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period), per Kaplan-Meier.
Time frame: From the first dose of treatment up to study completion, up to 5 years
Overall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates
Overall survival is defined as the time from the date of randomization to the date of death (including the survival follow-up period) per Kaplan-Meier (KM).
Time frame: From the first dose of treatment to study completion, up to 5 years
Trough Plasma Concentrations for Asciminib
Measured concentration at the end of a dosing interval at steady state (taken directly before next administration)
Time frame: Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
PK Parameter: Cmax for Asciminib
Maximum (peak) observed plasma concentration after dose administration (mass x volume-1).
Time frame: Week 2 Day 1 at pre-dose, 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
PK Parameter: Tmax for Asciminib
Time to reach maximum (peak) plasma concentration after dose administration (time). Actual sampling times were taken into consideration for the pharmacokinetic analysis.
Time frame: Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
PK Parameter: AUC0-12h for Asciminib
Area under the plasma concentration-time curve from time zero to 12 hours (mass x time x volume-1)
Time frame: Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
PK Parameter: CL/F for Asciminib
Total apparent body clearance of drug from the plasma after oral administration (volume x time-1).
Time frame: Week 2 day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
Participants were treated at a total of 84 sites.
| Milestone | Asciminib | Bosutinib |
|---|---|---|
| Started | 157 | 76 |
| Treated | 156 | 76 |
| Not treated | 1 | 0 |
| Switched to receive asciminib | 0 | 25 |
| Completed | 77 | 8 |
| Not completed | 80 | 68 |
| Withdrew: Lack of efficacy | 40 | 28 |
| Withdrew: Physician decision | 13 | 7 |
| Withdrew: Adverse event | 11 | 21 |
| Withdrew: Subject/guardian decision | 6 | 7 |
| Withdrew: Death | 4 | 0 |
| Withdrew: Progressive disease | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Not treated | 1 | 0 |
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
| Percentage of participants | Asciminib | Bosutinib |
|---|---|---|
| Major Molecular Response (MMR) Rate at 24 Weeks | 25.48 | 13.16 |
MMR at 96 weeks was defined as the percentage of participants with MMR at 96 weeks. MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
| Percentage of participants | Asciminib | Bosutinib |
|---|---|---|
| Major Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint) | 37.58 | 15.79 |
Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.
| Participants | Asciminib | Bosutinib |
|---|---|---|
| at Week 24 | 42 | 15 |
| at Week 48 | 41 | 13 |
| at Week 72 | 39 | 12 |
| at Week 96 | 41 | 10 |
| at Week 120 | 37 | 7 |
| at Week 144 | 35 | 4 |
Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.
| Participants | Asciminib | Bosutinib |
|---|---|---|
| by Week 24 | 42 | 15 |
| by Week 48 | 47 | 22 |
| by Week 72 | 49 | 22 |
| by Week 96 | 51 | 22 |
| by Week 120 | 51 | 22 |
| by Week 144 | 51 | 22 |
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
| Participants | Asciminib | Bosutinib |
|---|---|---|
| at Week 36 | 41 | 9 |
| at Week 48 | 46 | 10 |
| at Week 60 | 52 | 11 |
| at Week 72 | 52 | 12 |
| at Week 84 | 50 | 10 |
| at Week 108 | 53 | 11 |
| at Week 120 | 57 | 8 |
| at Week 132 | 58 | 8 |
| at Week 144 | 59 | 7 |
| at Week 156 | 53 | 8 |
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR. Overall time point has the count indicating participants achieving MMR at any time during the study.
| Participants | Asciminib | Bosutinib |
|---|---|---|
| by Week 4 | 3 | 0 |
| by Week 8 | 12 | 4 |
| by Week 12 | 30 | 7 |
| by Week 16 | 39 | 8 |
| by Week 24 | 43 | 11 |
| by Week 36 | 51 | 13 |
| by Week 48 | 55 | 15 |
| by Week 60 | 60 | 16 |
| by Week 72 | 60 | 17 |
| by Week 84 | 63 | 17 |
| by Week 96 | 67 | 18 |
| by Week 108 | 67 | 18 |
| by Week 120 | 68 | 18 |
| by Week 132 | 70 | 18 |
| by Week 144 | 71 | 18 |
| by Week 156 | 71 | 18 |
| Overall | 74 | 19 |
Time to MMR was defined as the time from the date of randomization to the date of the first documented MMR.
| Weeks | Asciminib | Bosutinib |
|---|---|---|
| Time to Major Molecular Response (MMR) | 16.3 (4 to 216) | 24.1 (7 to 216) |
Duration of MMR was defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to Accelerated phase (AP) or Blast crisis (BC), or Chronic myeloid leukemia (CML)-related death.
| Weeks | Asciminib | Bosutinib |
|---|---|---|
| Duration of Major Molecular Response (MMR) | NA (NA to NA) | NA (NA to NA) |
Time to CCyR was defined as the time from the date of randomization to the date of the first documented CCyR.
| Weeks | Asciminib | Bosutinib |
|---|---|---|
| Time to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR | 24.3 (23 to 216) | 24.3 (12 to 53) |
Duration of CCyR was defined as the time between date of first documented CCyR and the earliest date of loss of CCyR, progression to AP/BC, or CML-related death for participants in the Cytogenetic Responder Set. The time was censored at the last cytogenetic assessment date on treatment for participants for whom none of the events was reported or last PCR evaluation on treatment indicating MMR.
| Weeks | Asciminib | Bosutinib |
|---|---|---|
| Duration of Complete Cytogenetic Response (CCyR) | NA (NA to NA) | NA (64.1 to NA) |
TTF was defined as the time from date of randomization to an event of treatment failure. Treatment failure was defined as meeting a lack of efficacy criterion or discontinuing treatment due to any reason.
| Year | Asciminib | Bosutinib |
|---|---|---|
| Time to Treatment Failure (TTF) | 2.4 (1.0 to NA) | 0.5 (0.5 to 0.6) |
Progression-free survival was defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period), per Kaplan-Meier.
| Percentage of participants | Asciminib | Bosutinib |
|---|---|---|
| 1 year | 95.6 (90.4 to 98.0) | 91.4 (80.2 to 96.4) |
| 3 years | 85.7 (77.5 to 91.0) | 84.9 (69.6 to 92.9) |
| 5 years | 68.5 (47.2 to 82.7) | 64.6 (38.4 to 81.9) |
Overall survival is defined as the time from the date of randomization to the date of death (including the survival follow-up period) per Kaplan-Meier (KM).
| Percentage of participants | Asciminib | Bosutinib |
|---|---|---|
| 1 year | 97.3 (92.9 to 99.0) | 98.6 (90.2 to 99.8) |
| 3 years | 92.4 (86.7 to 95.7) | 96.9 (88.0 to 99.2) |
| 5 years | 89.4 (83.1 to 93.5) | 90.0 (78.9 to 95.4) |
Measured concentration at the end of a dosing interval at steady state (taken directly before next administration)
| ng/mL | Asciminib |
|---|---|
| Trough Plasma Concentrations for Asciminib | 238 (145 to 551) |
Maximum (peak) observed plasma concentration after dose administration (mass x volume-1).
| ng/mL | Asciminib |
|---|---|
| PK Parameter: Cmax for Asciminib | 971 ± 48.3 |
Time to reach maximum (peak) plasma concentration after dose administration (time). Actual sampling times were taken into consideration for the pharmacokinetic analysis.
| hour (hr) | Asciminib |
|---|---|
| PK Parameter: Tmax for Asciminib | 1.92 (0.983 to 3.33) |
Area under the plasma concentration-time curve from time zero to 12 hours (mass x time x volume-1)
| ng*hr/mL | Asciminib |
|---|---|
| PK Parameter: AUC0-12h for Asciminib | 5810 ± 32.9 |
Total apparent body clearance of drug from the plasma after oral administration (volume x time-1).
| L/hr | Asciminib |
|---|---|
| PK Parameter: CL/F for Asciminib | 7.29 (3.73 to 11.5) |
Collected over Adverse events (AEs) & on-treatment deaths were collected from the first dose of study treatment up to 30 days after last dose of study medication. The maximum duration of treatment exposure was 256.3 weeks for asciminib, and 239.3 weeks for bosutinib.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| On-treatment Period Asciminib | 5/156 (3.2%) | 34/156 (21.8%) | 130/156 (83.3%) |
| On-treatment Period Bosutinib | 1/76 (1.3%) | 20/76 (26.3%) | 72/76 (94.7%) |
| On-treatment Period: Switched From Bosutinib to Asciminib | 0/25 (0%) | 2/25 (8%) | 20/25 (80%) |
| Post-treatment Period Asciminib | 11/135 (8.1%) | 1/135 (0.7%) | 7/135 (5.2%) |
| Post-treatment Period Bosutinib | 8/61 (13.1%) | 0/61 (0%) | 3/61 (4.9%) |
| Post-treatment Period: Switched From Bosutinib to Asciminib | 3/24 (12.5%) | 0/24 (0%) | 0/24 (0%) |
| Event | On-treatment Period Asciminib | On-treatment Period Bosutinib | On-treatment Period: Switched From Bosutinib to Asciminib | Post-treatment Period Asciminib | Post-treatment Period Bosutinib | Post-treatment Period: Switched From Bosutinib to Asciminib |
|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/156 | 0/76 | 1/25 | 0/135 | 0/61 | 0/24 |
| Mesenteric arterial occlusionGastrointestinal disorders | 0/156 | 0/76 | 1/25 | 0/135 | 0/61 | 0/24 |
| Mesenteric artery thrombosisGastrointestinal disorders | 1/156 | 0/76 | 1/25 | 0/135 | 0/61 | 0/24 |
| Cholecystitis acuteHepatobiliary disorders | 0/156 | 0/76 | 1/25 | 0/135 | 0/61 | 0/24 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/156 | 0/76 | 1/25 | 0/135 | 0/61 | 0/24 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/156 | 0/76 | 1/25 | 0/135 | 0/61 | 0/24 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/156 | 3/76 | 0/25 | 0/135 | 0/61 | 0/24 |
| RashSkin and subcutaneous tissue disorders | 0/156 | 2/76 | 0/25 | 0/135 | 0/61 | 0/24 |
| Cardiac failureCardiac disorders | 3/156 | 0/76 | 0/25 | 0/135 | 0/61 | 0/24 |
| Urinary tract infectionInfections and infestations | 3/156 | 0/76 | 0/25 | 0/135 | 0/61 | 0/24 |
| Event | On-treatment Period Asciminib | On-treatment Period Bosutinib | On-treatment Period: Switched From Bosutinib to Asciminib | Post-treatment Period Asciminib | Post-treatment Period Bosutinib | Post-treatment Period: Switched From Bosutinib to Asciminib |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 20/156 | 55/76 | 1/25 | 0/135 | 0/61 | 0/24 |
| NauseaGastrointestinal disorders | 18/156 | 35/76 | 4/25 | 0/135 | 0/61 | 0/24 |
| NeutropeniaBlood and lymphatic system disorders | 30/156 | 13/76 | 9/25 | 1/135 | 0/61 | 0/24 |
| ThrombocytopeniaBlood and lymphatic system disorders | 36/156 | 11/76 | 8/25 | 2/135 | 0/61 | 0/24 |
| Alanine aminotransferase increasedInvestigations | 8/156 | 23/76 | 1/25 | 0/135 | 2/61 | 0/24 |
| VomitingGastrointestinal disorders | 12/156 | 19/76 | 2/25 | 0/135 | 0/61 | 0/24 |
| RashSkin and subcutaneous tissue disorders | 15/156 | 17/76 | 2/25 | 1/135 | 0/61 | 0/24 |
| Aspartate aminotransferase increasedInvestigations | 9/156 | 16/76 | 1/25 | 0/135 | 1/61 | 0/24 |
| HeadacheNervous system disorders | 30/156 | 12/76 | 4/25 | 1/135 | 0/61 | 0/24 |
| Abdominal painGastrointestinal disorders | 14/156 | 12/76 | 1/25 | 0/135 | 0/61 | 0/24 |
Full Analysis Set (FAS): The FAS comprised of all randomized patients.
| Age, Continuous(years) | Asciminib | Bosutinib | Total |
|---|---|---|---|
| Mean | 51.0 ± 13.49 | 51.0 ± 13.95 | 51.0 ± 13.61 |
| Sex: Female, Male(Participants) | Asciminib | Bosutinib | Total |
|---|---|---|---|
| Female | 75 | 45 | 120 |
| Male | 82 | 31 | 113 |
| Race/Ethnicity, Customized(participants) | Asciminib | Bosutinib | Total |
|---|---|---|---|
| White | 118 | 56 | 174 |
| Asian | 22 | 11 | 33 |
| Black or African American | 8 | 2 | 10 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Other | 5 | 7 | 12 |
| Unknown | 3 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Oct 2017 to primary completion in May 2020, 30 months.
Results were first posted in Feb 2022, 1 year 8 months after primary completion.
Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asciminib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →